Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in immunology 2015-11, Vol.6, p.588-588
Hauptverfasser: Garg, Abhishek D, Galluzzi, Lorenzo, Apetoh, Lionel, Baert, Thais, Birge, Raymond B, Bravo-San Pedro, José Manuel, Breckpot, Karine, Brough, David, Chaurio, Ricardo, Cirone, Mara, Coosemans, An, Coulie, Pierre G, De Ruysscher, Dirk, Dini, Luciana, de Witte, Peter, Dudek-Peric, Aleksandra M, Faggioni, Alberto, Fucikova, Jitka, Gaipl, Udo S, Golab, Jakub, Gougeon, Marie-Lise, Hamblin, Michael R, Hemminki, Akseli, Herrmann, Martin, Hodge, James W, Kepp, Oliver, Kroemer, Guido, Krysko, Dmitri V, Land, Walter G, Madeo, Frank, Manfredi, Angelo A, Mattarollo, Stephen R, Maueroder, Christian, Merendino, Nicolò, Multhoff, Gabriele, Pabst, Thomas, Ricci, Jean-Ehrland, Riganti, Chiara, Romano, Erminia, Rufo, Nicole, Smyth, Mark J, Sonnemann, Jürgen, Spisek, Radek, Stagg, John, Vacchelli, Erika, Vandenabeele, Peter, Vandenberk, Lien, Van den Eynde, Benoit J, Van Gool, Stefaan, Velotti, Francesca, Zitvogel, Laurence, Agostinis, Patrizia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The immunogenicity of malignant cells has recently been acknowledged as a critical determinant of efficacy in cancer therapy. Thus, besides developing direct immunostimulatory regimens, including dendritic cell-based vaccines, checkpoint-blocking therapies, and adoptive T-cell transfer, researchers have started to focus on the overall immunobiology of neoplastic cells. It is now clear that cancer cells can succumb to some anticancer therapies by undergoing a peculiar form of cell death that is characterized by an increased immunogenic potential, owing to the emission of the so-called "damage-associated molecular patterns" (DAMPs). The emission of DAMPs and other immunostimulatory factors by cells succumbing to immunogenic cell death (ICD) favors the establishment of a productive interface with the immune system. This results in the elicitation of tumor-targeting immune responses associated with the elimination of residual, treatment-resistant cancer cells, as well as with the establishment of immunological memory. Although ICD has been characterized with increased precision since its discovery, several questions remain to be addressed. Here, we summarize and tabulate the main molecular, immunological, preclinical, and clinical aspects of ICD, in an attempt to capture the essence of this phenomenon, and identify future challenges for this rapidly expanding field of investigation.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2015.00588